Past, present, and emerging antifungals against Fusarium and other rare non- aspergillus hyalohyphomycetes: a narrative review

Key Points

• The aim is to evaluate available and emerging antifungals for treating rare mold infections.
• Conducted a narrative review of antifungal medications.
• Explored the clinical efficacy of rezafungin and ibrexafungerp.
• Assessed fosmanogepix and olorofim's potential against hyalohyphomycoses.
• Reviewed in-vitro susceptibility variability of antifungals.
• Rezafungin and ibrexafungerp show limited clinical data and effectiveness.
• Fosmanogepix and olorofim demonstrate potential for treating invasive molds.
• Notable variability in antifungal susceptibility was observed against hyalohyphomycetes.
• Future studies are emphasized to better understand clinical applications.